Neurophth Announces First Patient Dosed in China for Its Second Ophthalmic Gene Therapy NFS-02

Today (August 17), Neurophth Biotechnology Co., Ltd. ("Neurophth") announced that the first patient has been enrolled and dosed in China for the international multicenter Phase I/II clinical trial of its second ophthalmic gene therapy drug, NFS-02 (rAAV2-ND1), used to treat Leber's Hereditary Optic Neuropathy caused by ND1 mutations (ND1-LHON).

Neurophth is conducting a Phase I/II, multi-center, single-arm, open-label, dose-finding clinical study in both China and the United States to evaluate the safety, efficacy, and tolerability of gene therapy for ND1 mutation-related Leber's Hereditary Optic Neuropathy (LHON). The project received clinical trial approval from the U.S. FDA in December 2022 and obtained IND approval from China's National Medical Products Administration (NMPA) on April 17, 2023. Professor Jia Qu, Director of the Ophthalmology Department at the Eye Hospital of Wenzhou Medical University, and Director Rong Zhou led their team in completing the first patient dosing procedure.

Editor: Muyan

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information, which does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.